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Context: Human leukocyte antigen (HLA) DQ haplotypes have the
strongest genetic association with type 1 diabetes (T1DM) risk.
Objective: The objective of the study was to analyze whether HLA
DQ alleles influence the development of antiislet autoantibodies, the
progression to T1DM among autoantibody-positive relatives, or both.
Design: The Diabetes Prevention Trial-1 screened more than 90,000
nondiabetic relatives of patients for cytoplasmic islet-cell autoanti-
body (ICA) expression between 1994 and 2002.
Setting: The study was conducted in the general community.
Participants: The Diabetes Prevention Trial-1 found 2817 ICA-
positive relatives who were tested for biochemical autoantibodies
(GAD65, ICA512, and insulin) and HLA-DQ haplotypes, and 2796 of
them were followed up for progression to diabetes for up to 8 yr
(median, 3.6 yr).
Main Outcome Measure: Progression to T1DM was measured.
Results:High-risk DQ haplotypes and genotypes were associated with
a higher percentage of relatives expressing multiple biochemical auto-
antibodies and higher T1DM risk (e.g., respectively, 59 and 36% at 5 yr
for carriers of theDQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201ge-
notype). Thenumber of autoantibodies expressed significantly increased
T1DM risk and across different DQ genotypes, autoantibody positivity
directly correlated with diabetes risk. However, multivariate analyses
indicated that the influence of most genotypes on T1DM risk was not
independent from autoantibody expression, with the possible exception
of DQA1*0102-DQB1*0602. Specific genotypic combinations conferred
5-yr diabetes risks significantly lower (e.g. 7%-DQA1*0201-DQB1*0201/
DQA1*0501-DQB1*0201 and 14%-DQA1*0301-DQB1*0301/DQA1*
0501-DQB1*0201) than when those haplotypes were found in other
combinations.
Conclusion: HLA DQ alleles determine autoantibody expression,
which is correlated with diabetes progression. Among autoantibody-
positive relatives, most HLA DQ genotypes did not further influence
T1DM risk. (J Clin Endocrinol Metab 91: 1705–1713, 2006)
THEMAJOR HISTOCOMPATIBILITY complex accountsfor approximately 50% of the familial aggregation of
type 1 diabetes (T1DM) (1).High-risk alleles, haplotypes, and
genotypes as well as protective alleles, haplotypes, and ge-
notypes have been identified. DQ haplotypes have the stron-
gest associationwith diabetes, butDR alleles canmodify risk.
Most studies assessing the influence of human leukocyte
antigen (HLA) haplotypes on T1DM have analyzed popu-
lations of individuals with known T1DM. The Diabetes Pre-
vention Trial Type 1 (DPT-1) (2) afforded the opportunity of
prospectively evaluating progression to diabetes. We aimed
to analyze the influence of HLA class II haplotypes and
genotypes on antiislet autoantibody expression and,whether
in relatives with positive biochemical autoantibodies, T1DM
risk is influenced byHLA class II. Given the size of the DPT-1
cohort expressing cytoplasmic islet-cell autoantibodies (ICA)
who were all HLA typed (n 2817), we were able to analyze
the influence of haplotypes when found in specific genotypic
combinations (DQ of both sixth chromosomes) on autoanti-
body expression and progression to diabetes.
Subjects and Methods
Subjects
Identification. The DPT-1 screened 97,272 first- and second-degree rela-
tives of individuals with T1DM who had been diagnosed before age 45
yr. To have been eligible for screening, an individual must have been a
first-degree relative of a patient with T1DM and between ages 3 and 45
yr or second-degree relative between ages 3 and 20 yr. A flow chart
depicting the ascertainment and follow-up of the cohort is illustrated in
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Fig. 1. Relatives who were found to be ICA were staged to further
assess risk. Staging consisted of repeat ICA testing, determination of
insulin antibodies,HLA-DQ typing, an iv glucose tolerance test, and oral
glucose tolerance testing (OGTT). Relatives with DQA1*0102-
DQB1*0602 [in linkage disequilibrium (LD) with DR2] were excluded
(noneligible) from the DPT-1. Here we report the results of the 2817
relatives whowere HLA typed, were ICA positive, andwere also tested,
on the screening sample, for glutamic acid decarboxylase (GAD65) au-
toantibodies (GAD65A), insulin autoantibodies, and ICA512 autoanti-
bodies (ICA512A). Of the 2817, 51%weremales, 88%were non-Hispanic
white, and 89.8% were first-degree relatives.
Follow-up.Of the 2817 ICA subjects, 2796 subjects were followed up for
up to 8 yr (median 3.6 yr). Of these 2796 subjects, those who were
enrolled in DPT-1 intervention studies included those either with con-
firmed positivity for ICA and insulin autoantibodies or those with con-
firmed ICA and low first phase of insulin release or abnormal, but not
diabetic, OGTT at baseline visits. The development of diabetes in these
DPT-1 subjects enrolled in intervention studies was assessed by formal
OGTT every 6 months or confirmed diabetes by American Diabetes
Association criteria. For the remaining subjects, the development of
diabetes was assessed via a follow-up questionnaire, which was sent to
the nondiabetic screened subjects. For the DQA1*0102-DQB1*0602 sub-
jects, the source of follow-up came from either available staging data or
the follow-up questionnaire (3). The analyses presented here include the
development of T1DM in 441 subjects.
Written consent was obtained from all subjects or their parents.
Antiislet autoantibodies
Autoantibodies against GAD65, ICA512 (IA-2), and insulin (termed
biochemical autoantibodies for this manuscript, as opposed to cytoplas-
mic islet-cell autoantibodies, or ICA) were measured in an ancillary
study of DPT-1 (4, 5). Cytoplasmic ICAs were determined on frozen
sections of human pancreas (6). Samples were considered positive at 10
or more Juvenile Diabetes Foundation units. In the Immunology of
Diabetes SocietyCombinatorialAutoantibodyWorkshop (Orvieto, Italy,
November 1995), this ICA assay had 100% specificity and 74.4% sensi-
tivity for new-onset patients aged younger than 30 yr.
GAD65A and ICA512A levels were measured simultaneously in a
combinedGAD65A/ ICA512A radioassay, as previously described (full-
length GAD65 and ICA512bdc cDNA clones) (7). The assay was per-
formed in 96-well filtration plates with autoantibody bound [3H]GAD65
and [35S]ICA512 precipitated with protein A-Sepharose. The cut points
were set at indices of 0.032 (GAD65A) and 0.049 (ICA512A), the 99th
percentiles of 198 controls. The interassay coefficients of variation were
6.5 and 9.6%, respectively, for GAD65A and ICA512A assays. In the
Immunology of Diabetes Society Combinatorial Workshop, for patients
younger than 30 yr, the assay specificitywas 99 and 100%, and sensitivity
was 83.7 and 74.4% for GAD65A and ICA512A, respectively. In the 2003
Diabetes Antibody Standardization Program proficiency testing, the
assay specificity was 98 and 100%, and sensitivity was 84 and 58% for
GAD65A and ICA512A, respectively.
Insulin autoantibodies were measured with 125I-insulin in standard
96-well filtration plates that quantitate precipitated 125I-insulin with a
multichannel 96-well -counter. Scintillation fluid is directly added to
the 96-well plate (Top-Counter scintillation counter) (8). An index was
determined based on the difference in counts per minute between wells
without and with cold insulin. The cut point for positivity was set at the
99th percentile of healthy controls (0.01 and 0.02 index, respectively, for
the Denver and Boston laboratories). In the 2003 Diabetes Antibody
Standardization Program proficiency testing, the microinsulin autoan-
tibody assay (mIAA) assay sensitivity was 74 and 56% and specificity 90
and 98%, respectively, for the Denver and Boston laboratories, and the
correlation coefficient between both laboratories was r  0.90, P 
0.0001.
Among DPT-1 eligible and screened relatives who were positive for
ICA, ICA512A, mIAA, or GAD65A, 21.9, 46, 41, and 34.8% progressed
to diabetes, respectively, comparedwith 10.2, 10.8, 16.1, and 9.5% among
relatives who were negative for each single autoantibody (all compar-
isonsP 0.0001). Among relativeswhowere positive for none, one, two,
or three biochemical autoantibodies (e.g. ICA512A, mIAA, GAD65A),
7.9, 27.8, 42.5, and 47.6% progressed to diabetes (P  0.0001).
HLA-DQ typing
HLA-DQA and DQB alleles were typed as part of the DPT-1 study
using sequence-specific oligonucleotide probes in the DPT-1 HLA Core
Laboratory (Denver, CO) (9). The DQA1*0101-DQB1*0501 haplotype (in
LDwith DR1) has been assigned an odds ratio of 1 when haplotypes are
compared for diabetes protection or risk (neutral haplotype) (10).
FIG. 1. Flow chart describing the
cohort and its follow-up.
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Statistical analysis
Categorical variables were analyzed using 2 tests or Fisher’s exact
tests, depending on cell size. Time-to-event analytic methods included
Kaplan-Meier estimates (with log-log confidence intervals) and log-
rank. Life table analysis of progression to diabetes among autoantibody-
positive relatives was based only on screening sample results. Addi-
tionally, time to progression to T1DM was modeled using both
univariate and multivariate Cox-proportional hazard models. Indepen-
dent variables considered included DR status and number of positive
antibodies observed on all available samples (e.g. screening and staging).
Statistical analyseswere performed using SAS (SAS Institute, Cary, NC),
True Epistat (Epistat Services, Richardson, TX), and Prism (GraphPad
Software, San Diego, CA) software using a two-sided significance level
of 0.05.
Results
In this group of 2817 relatives of patients with T1DMwho
screened positive for ICA, the most frequent haplotypes ex-
pressed were the high-risk DQA1*0301-DQB1*0302 (in LD
with DR4) in 50% and DQA1*0501-DQB1*0201 (in LD with
DR3) in 46%. The protective haplotypes DQA1*0102-
DQB1*0602 (in LD with DR2), DQA1*0201-DQB1*0303 (in
LD with DR7) and DQA1*0101-DQB1*0503 (in LD with
DR14) were found, respectively, in 8, 2, and 2%. Almost 20%
of the relatives had the highest risk genotype DQA1*0501-
DQB1*0201/DQA1*0301-DQB1*0302, and all other geno-
types were present in less than 7% of relatives.
Influence of HLA haplotypes and genotypes on number of
autoantibodies expressed
There was a wide variation in the percentage of ICA
relatives expressing biochemical autoantibodies relative to
DQ haplotypes, ranging from 57% of 44 relatives with
DQA1*0301-DQB1*0201 (in LD with DR9) expressing mul-
tiple (two or more) biochemical autoantibodies to 8% of 238
relatives with DQA1*0102-DQB1*0602 expressing multiple
biochemical autoantibodies. Almost 50% of DQA1*0301-
DQB1*0302 and 38% of DQA1*0501-DQB1*0201 relatives
were positive for multiple biochemical autoantibodies. Of
note, 39% of relatives with the DQA1*0301-DQB1*0301 hap-
lotype, which is in LD with DR4 and has aspartic acid at
amino acid 57 of DQB1, expressed multiple biochemical an-
tibodies. Almost 80% of relatives with the protective haplo-
type DQA1*0102-DQB1*0602 expressed no biochemical au-
toantibody, compared with 45% among 2579 relatives
without this haplotype (P  0.0001). Similarly, 79 and 71%,
respectively, of relatives with DQA1*0201-DQB1*0303 or
DQA1*0101-DQB1*0503 expressed no biochemical antibody,
compared with 47% without DQA1*0201-DQB1*0303 (n 
2749, P  0.0001) and 47% of relatives without DQA1*0101-
DQB1*0503 (n  2766, P  0.001).
Table 1 indicates the percentage of subjects expressing
multiple (2) biochemical autoantibodies by genotypes and
odds ratios relative to the highest risk genotype DQA1*0501-
DQB1*0201/DQA1*0301-DQB1*0302. Of note, the frequency
of positivity formultiple biochemical autoantibodieswas not
different in relatives with DQA1*0301-DQB1*0302/
DQA1*0501-DQB1*0201 (59%) and relatives who were ho-
mozygous for DQA1*0301-DQB1*0302 (57%, P  0.79),
whereas it was higher than relatives who were homozygous
for DQA1*0501-DQB1*0201 (30%, P 0.0001). The frequency
of positivity for multiple autoantibodies was not signifi-
cantly different between relatives with DQA1*0501-
DQB1*0201/DQA1*0501-DQB1*0201 (30%), relatives with
DQA1*0501-DQB1*0201/DQA1*0101-DQB1*0501 (26%),
and relatives with DQA1*0101-DQB1*0501/DQA1*0101-
DQB1*0501 (26%) (P  0.60). Relatives with DQA1*0301-
DQB1*0302/DQA1*0101-DQB1*0501 had an intermediate
prevalence (47%).
Genotypes containing the protective DQA1*0102-
DQB1*0602 haplotype were associated with low frequencies
of multiple autoantibody expressivity, even when combined
with high-risk haplotypes DQA1*0301-DQB1*0302 or
DQA1*0501-DQB1*0201 (4 and 10%, respectively, expressed
multiple biochemical autoantibodies).
Positivity for each of the biochemical autoantibodies was
significantly more prevalent in relatives with the high-risk
haplotypes DQA1*0301-DQB1*0302 and DQA1*0501-
DQB1*0201 than in relatives with protective or neutral hap-
lotypes. However, mIAA positivity occurred in 22% of
DQA1*0101-DQB1*0501 relatives,which is not different from
22% in DQA1*0301-DQB1*0302 relatives (P  0.83), and
higher than 17% in DQA1*0501-DQB1*0201 relatives (P 
0.0005). The frequency of positivity for specific biochemical
autoantibodies was not significantly different between rel-
atives with the DQA1*0501-DQB1*0201/DQA1*0301-
DQB1*0302 genotype and relatives who were homozygous
for DQA1*0301-DQB1*0302. Relatives who were homozy-
gous for DQA1*0501-DQB1*0201 were significantly less
likely to be positive for each of the biochemical autoanti-
bodies than those who were DQA1*0301-DQB1*0302 ho-
mozygous (data not shown).
Influence of HLA haplotypes and genotypes on progression
to T1DM
Of the 2817 relatives who were HLA typed and tested for
autoantibodies, 2796 subjects were prospectively followed
up until progression to T1DM.
Overall progression to T1DM by HLA haplotypes and genotypes,
regardless of autoantibody status. Life table-estimated risk of
progression to diabetes at 5 yr was 32% in relatives with
DQA1*0301-DQB1*0302, significantly higher than 15% in rel-
atives without this haplotype (P 0.001). After DQA1*0301-
DQB1*0302, the haplotype with the highest diabetes risk,
among those haplotypes that were present in more than 15
subjects and therefore suitable for life table analysis, was
DQA1*0301-DQB1*0201, with 26% risk at 5 yr. Five-year
diabetes risk was 25% in DQA1*0501-DQB1*0201 relatives,
23% in DQA1*0101-DQB1*0501 relatives, and 20% in
DQA1*0301-DQB1*0301 relatives. Progression to T1DM at 5
yr in relatives with the protective DQA1*0102-DQB1*0602
(n 238) or DQA1*0201-DQB1*0303 (n 67) was 1 and 11%,
respectively, significantly lower than relatives without those
haplotypes (respectively, 25%, P 0.001 and 24%, P 0.04).
However, progression to T1DM in 51 relatives with
DQA1*0101-DQB1*0503 was 19%, not significantly different
from relatives without this haplotype (24%, P  0.288). Life-
table analyses of progression to T1DM by different haplo-
types are available in supplemental Table 1 published on The
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Relatives bearing the DQA1*0501-DQB1*0201/
DQA1*0301-DQB1*0302 genotype (n  521) had a signifi-
cantly higher risk of T1DM (36% at 5 yr) than relatives with-
out this genotype (20%, P 0.001) (Fig. 2A). Diabetes risk at
5 yr was 36% in 175 relatives homozygous for DQA1*0301-
DQB1*0302, and 34% in 138 relatives homozygous for
DQA1*0501-DQB1*0201 but only 14% in 19 relatives with
DQA1*0101-DQB1*0501/DQA1*0101-DQB1*0501, 3% for
72 relatives with DQA1*0102-DQB1*0602/DQA1*0501-
DQB1*0201, and 2% for 56 relatives with DQA1*0102-
DQB1*0602/DQA1*0301-DQB1*0302. There were only seven
subjects with DQA1*0102-DQB1*0602/DQA1*0102-DQB1*0602,
and, at 5 yr of follow-up, none had developed diabetes. Lifetable
analyses of progression toT1DMbydifferent genotypes are avail-
able insupplementalTable2publishedonTheEndocrineSociety’s
Journals Online web site at http://jcem.endojournals.org.
Progression to T1DM by HLA haplotype and genotype in autoan-
tibody-positive relatives.Univariate analysis indicated that, re-
gardless of genotype, an increasing number of positive au-
toantibodies significantly increased the hazard ratio (HR) of
progression to T1DM relative to positivity for ICA only: HR
of 0.161 for no positive autoantibodies (se 0.60, P 0.002),
2.106 for one autoantibody (se  0.331, P  0.024), 4.924 for
two autoantibodies (se  0.187, P  0.0001), 9.901 for three
autoantibodies (se  0.171, P  0.0001), and 9.822 for four
autoantibodies (se  0.184, P  0.0001).
In relatives carrying the DQA1*0301-DQB1*0302,
TABLE 1. Expression of multiple (2) biochemical autoantibodies by genotypes
Genotype (DQ) Proportion (%) Odds ratio (95% CI) P value
0501-0201/0301-0302 305/521 (58.5) N/A (reference) N/A
0101-0501/0101-0501 5/19 (26.3) 0.249 (0.088–0.702) 0.008
0101-0501/0102-0604 5/16 (12.5) 0.317 (0.109–0.925) 0.038
0101-0501/0102-0602 0/12 (0) 0.028 (0.002–0.474)a 2.84E-05
0101-0501/0501-0201 22/85 (25.9) 0.243 (0.145–0.408) 1.61E-08
0101-0501/0301-0302 58/124 (46.8) 0.638 (0.427–0.938) 0.026
0101-0501/0301-0301 23/39 (59.0) 1.002 (0.517–1.942) 1.0
0101-0501/0501-0301 2/24 (8.3) 0.063 (0.015–0.272) 5.76E-07
0101-0501/0103-0603 2/12 (16.7) 0.139 (0.030–0.643) 0.005
0101-0501/0201-0201 4/18 (22.2) 0.199 (0.065–0.613) 0.003
0102-0602/0102-0604 1/14 (7.1) 0.054 (0.007–0.413) 1.02E-04
0102-0602/0501-0201 7/72 (9.7) 0.075 (0.034–0.167) 2.6E-16
0102-0602/0301-0302 2/56 (3.6) 0.026 (0.006–0.107) 2.4E-17
0102-0602/0301-0301 1/11 (9.1) 0.070 (0.009–0.548) 0.001
0102-0602/0501-0301 1/23 (4.4) 0.032 (0.004–0.237) 8.21E-08
0102-0602/0201-0201 1/11 (9.1) 0.070 (0.009–0.549) 0.001
0102-0502/0501-0201 5/19 (26.3) 0.249 (0.088–0.702) 0.004
0102-0502/0301-0302 8/21 (38.1) 0.429 (0.175–1.053) 0.071
0501-0201/0102-0604 10/45 (22.2) 0.199 (0.097–0.411) 1.4E-06
0501-0201/0101-0503 0/17 (0) 0.020 (0.001–0.333)a 4.05E-07
0501-0201/0501-0201 42/138 (30.3) 0.305 (0.204–0.456) 3.02E-09
0501-0201/0301-0301 23/84 (27.4) 0.269 (0.158–0.438) 6.8E-08
0501-0201/0501-0301 14/80 (17.5) 0.148 (0.081–0.270) 2.14E-12
0501-0201/0103-0603 8/41 (19.5) 0.169 (0.077–0.373) 9.1E-07
0501-0201/0201-0201 22/88 (25.0) 0.232 (0.139–0.388) 3.3E-09
0501-0201/0201-0303 7/24 (29.2) 0.140 (0.047–0.414) 6.1E-05
0501-0201/0401-0402 4/27 (14.8) 0.121 (0.041–0.356) 8.6E-06
0301-0302/0102-0604 27/63 (42.9) 0.523 (0.308–0.887) 0.021
0301-0302/0101-0503 4/11 (36.4) 0.398 (0.115–1.378) 0.214
0301-0302/0301-0302 100/175 (57.1) 0.951 (0.673–1.346) 0.79
0301-0302/0301-0301 30/57 (52.6) 0.775 (0.448–1.340) 0.397
0301-0302/0501-0301 44/119 (37.0) 0.409 (0.271–0.617) 1.6E-05
0301-0302/0103-0603 28/60 (46.7) 0.610 (0.357–1.043) 0.069
0301-0302/0201-0201 34/83 (41.0) 0.484 (0.302–0.775) 0.003
0301-0302/0401-0402 18/38 (47.4) 0.627 (0.324–1.214) 0.176
0301-0302/0301-0201 10/12 (83.3) 3.485 (0.756–16.067) 0.135
0301-0301/0102-0604 11/22 (50.0) 0.697 (0.297–1.637) 0.508
0301-0301/0301-0301 9/13 (69.2) 1.568 (0.477–5.159) 0.574
0301-0301/0501-0301 2/20 (10) 0.078 (0.018–0.337) 2.2E-05
0301-0301/0103-0603 3/11 (27.3) 0.261 (0.069–0.997) 0.059
0301-0301/0201-0201 7/20 (35.0) 0.375 (0.147–0.956) 0.039
0501-0301/0102-0604 2/13 (15.4) 0.127 (0.028–0.578) 0.003
0501-0301/0501-0301 0/11 (0) 0.030 (0.002–0.517)a 6.7E-05
0501-0301/0103-0603 2/12 (16.7) 0.139 (0.030–0.643) 0.005
0501-0301/0201-0201 4/24 (16.7) 0.139 (0.047–0.414) 6.1E-05
0501-0301/0401-0402 0/13 (0) 0.026 (0.002–0.437)a 1.2E-05
0201-0201/0102-0604 5/20 (25.0) 0.232 (0.083–0.649) 0.003
0201-0201/0401-0402 9/20 (45) 0.570 (0.232–1.400) 0.251
Odds ratios are relative to DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302 (in LD with DR3/4). Only genotypes present in more than 10
subjects are included. CI, Confidence interval; N/A, not applicable.
a Corrected logit estimators.
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DQA1*0501-DQB1*0201 or DQA1*0101-DQB1*0501 haplo-
types, development of T1DM was significantly different by
number of positive autoantibodies (higher number of posi-
tive autoantibodies increased T1DM risk) (data not shown).
Among relatives with DQA1*0102-DQB1*0602, progression
to diabetes was also different by number of positive auto-
antibodies (P  0.05), with higher number of positive auto-
antibodies affording greater diabetes risk, but the overall risk
was very small (3% with multiple autoantibodies).
A Cox-model prediction of T1DM indicated an indepen-
dent influence of both the presence of DQA1*0102-
DQB1*0602 (relative to its absence) (HR 0.258, P 0.0071)
and the number of positive autoantibodies (relative to ICA
positivity) (HR and P values, for no, one, two, three, and four
autoantibodies expressed, respectively, were 0.165 and
0.0026, 2.027 and 0.0325, 4.689 and  0.0001, 9.219 and less
than 0.0001, and 9.063 and  0.0001).
The number of positive autoantibodies significantly in-
creased diabetes risk in relativeswith the highest risk genotype
DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302 (P  0.001)
(Fig. 2B), DQA1*0301-DQB1*0302/DQA1*0301-DQB1*0302, or
DQA1*0501-DQB1*0201/DQA1*0501-DQB1*0201 (data not
shown).
For relatives who were positive for multiple biochemical auto-
antibodies at screening, survival analysis of progression to T1DM
wasnot different among thosewhohad the highest risk genotype
DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302, those who
were homozygous for DQA1*0301-DQB1*0302, those who
were homozygous for DQA1*0501-DQB1*0201, those with
DQA1*0101-DQB1*0501/DQA1*0301-DQB1*0302, those with
DQA1*0101-DQB1*0501/DQA1*0501-DQB1*0201, or those
with the DQA1*0102-DQB1*0602 haplotype (combined with
any other haplotype, i.e. DR2/Z). For the latter group of rela-
tives, it should be noted that the number was small (Fig. 3).
A series of multivariate analysis for prediction of T1DM,
each Cox model including a specific genotype alone and
FIG. 3. Survival analysis of progres-
sion to T1DM among relatives with
multiple positive biochemical autoanti-
bodies (two or more positives of
GAD65A, ICA512A or mIAA) at screen-
ing only, by HLA genotype.Numbers at
the bottom indicate numbers of rela-
tives still followedupat each timepoint.
FIG. 2. A, Survival analysis of progression to T1DM among 2796 DPT-1 eligible and tested subjects with and without the high-risk genotype
DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302. B, Survival analysis of progression to T1DM among 521 relatives with the high-risk genotype
DQA1*0301-DQB1*0302-DQA1*0501-DQB1*0201, by number of positive autoantibodies (ICA, GAD65A, ICA512A, mIAA) at screening.
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positivity for no, one, two, three, or four autoantibodies,
indicated that the effect of most genotypes on progression to
T1DM was not independent from autoantibody positivity.
Exceptions were genotypic combinations of DQA1*0501-
DQB1*0201 with DQA1*0301-DQB1*0301 (HR  0.375, se 
0.366, P 0.007), DQA1*0501-DQB1*0301 (HR 0.373, se
0.427, P 0.021), or DQA1*0201-DQB1*0201 (HR 0.326, se
 0.458, P  0.016). Table 2 illustrates a summary of these
analyses, for each genotype and positivity for all four
autoantibodies.
Diabetes risk at 5 yr for given genotypes correlated with
the percentage of relatives expressing no (r2  0.71, P 
0.0001), two (r2  0.67, P  0.0001), three (r2  0.35, P 
0.0003), at least one (1) (r2  0.69, P  0.0001, Figure 4), or
multiple (2) (r2  0.69, P  0.0001) biochemical autoanti-
bodies on the screening sample. In Fig. 4, only relatives with
DQA1*0102-DQB1*0502 (in LD with DR2) combined with
DQA1*0301-DQB1*0302 had an apparent higher risk of pro-
gression to diabetes (45%) than would be predicted by hav-
ing 57% of relatives with a biochemical autoantibody, but
there were only 21 DQA1*0102-DQB1*0502/DQA1*0301-
DQB1*0302 relatives with one or more positive autoantibod-
ies who were followed up for progression to diabetes.
Influence of specific haplotypic combinations (genotypes) on
autoantibody expression and progression to T1DM
The prevalence of positivity for multiple biochemical au-
toantibodies was significantly different among relatives who
had DQA1*0201-DQB1*0201 (in LD with DR7) combined
TABLE 2. Prediction of T1DM based on positivity for four autoantibodies (ICA, GAD65A, mIAA, and ICA512A), relative to ICA positivity,
and DQ genotype, relative to DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302
Genotype
By genotype By positivity for 4 autoantibodies Global P value
(df  6)HR (SE) P value HR (SE) P value
0101-0501/0101-0501 0.447 (0.713) 0.258 3.709 (0.362) 0.0003 0.0001
0101-0501/0102-0604 0.979 (0.717) 0.981 3.922 (0.0.362) 0.0002 0.0001
0101-0501/0102-0602 0.0 (390.1) 0.985 3.609 (0.361) 0.0004 0.0001
0101-0501/0501-0201 1.211 (0.266) 0.473 5.062 (0.361) 0.0001 0.0001
0101-0501/0301-0302 1.109 (0.187) 0.578 4.992 (0.350) 0.0001 0.0001
0101-0501/0301-0301 0.891 (0.313) 0.712 3.590 (0.348) 0.0002 0.0001
0101-0501/0501-0301 0 (616.0) 0.982 3.609 (0.361) 0.0004 0.0001
0101-0501/0103-0603 0 (930.0) 0.988 3.609 (0.361) 0.0004 0.0001
0101-0501/0201-0201 1.560 (0.603) 0.461 4.464 (0.368) 0.0001 0.0001
0102-0602/0102-0604 0 (888.6) 0.987 3.609 (0.361) 0.0004 0.0001
0102-0602/0501-0201 0.317 (0.730) 0.115 4.049 (0.369) 0.0002 0.0001
0102-0602/0301-0302 0.101 (1.012) 0.103 3.427 (0.351) 0.0004 0.0001
0102-0602/0301-0301 0 (392.4) 0.982 3.609 (0.361) 0.0004 0.0001
0102-0602/0501-0301 0 (827.5) 0.986 3.609 (0.361) 0.0004 0.0001
0102-0602/0201-0201 0 (915.5) 0.987 3.609 (0.361) 0.0004 0.0001
0102-0502/0501-0201 0.553 (0.712) 0.405 3.678 (0.362) 0.0003 0.0001
0102-0502/0301-0302 1.562 (0.387) 0.250 4.217 (0.358) 0.0001 0.0001
0501-0201/0102-0604 0.667 (0.391) 0.301 3.822 (0.352) 0.0001 0.0001
0501-0201/0101-0503 0.479 (1.026) 0.473 3.508 (0.355) 0.0001 0.0001
0501-0201/0501-0201 1.099 (0.192) 0.623 4.612 (0.349) 0.0001 0.0001
0501-0201/0301-0301 0.375 (0.366) 0.007 3.738 (0.349) 0.0002 0.0001
0501-0201/0501-0301 0.373 (0.427) 0.021 3.188 (0.325) 0.0004 0.0001
0501-0201/0103-0603 0.787 (0.425) 0.317 3.442 (0.338) 0.0003 0.0001
0501-0201/0201-0201 0.326 (0.458) 0.016 4.245 (0.361) 0.0001 0.0001
0501-0201/0201-0303 0.388 (0.715) 0.185 3.836 (0.361) 0.0002 0.0001
0501-0201/0401-0402 0.521 (0.370) 0.374 4.063 (0.370) 0.0002 0.0001
0301-0302/0102-0604 1.013 (0.271) 0.963 3.793 (0.345) 0.0001 0.0001
0301-0302/0101-0503 0.482 (1.000) 0.467 3.649 (0.361) 0.0003 0.0001
0301-0302/0301-0302 1.101 (0.152) 0.530 5.342 (0.332) 0.0001 0.0001
0301-0302/0301-0301 0.730 (0.357) 0.276 3.830 (0.357) 0.0002 0.0001
0301-0302/0501-0301 1.061 (0.202) 0.770 4.452 (0.296) 0.0001 0.0001
0301-0302/0103-0603 0.871 (0.280) 0.622 4.413 (0.359) 0.0001 0.0001
0301-0302/0201-0201 0.826 (0.246) 0.436 3.466 (0.333) 0.0002 0.0001
0301-0302/0401-0402 1.473 (0.280) 0.281 3.965 (0.359) 0.0001 0.0001
0301-0302/0301-0201 0.876 (0.390) 0.734 3.669 (0.360) 0.0003 0.0001
0301-0301/0102-0604 0.653 (0.455) 0.350 3.886 (0.361) 0.0002 0.0001
0301-0301/0301-0301 0.560 (0.584) 0.320 3.770 (0.359) 0.0002 0.0001
0301-0301/0501-0301 0.726 (0.590) 0.587 3.597 (0.352) 0.0003 0.0001
0301-0301/0103-0603 0.310 (1.006) 0.244 3.658 (0.298) 0.0001 0.0001
0301-0301/0201-0201 0.342 (0.712) 0.132 3.311 (0.349) 0.0006 0.0001
0501-0301/0102-0604 0.818 (1.027) 0.844 3.884 (0.368) 0.0002 0.0001
0501-0301/0501-0301 0 (833.1) 0.987 3.609 (0.361) 0.0004 0.0001
0501-0301/0103-0603 0.483 (1.013) 0.473 3.869 (0.362) 0.0002 0.0001
0501-0301/0201-0201 0.238 (1.006) 0.154 3.777 (0.360) 0.0002 0.0001
0501-0301/0401-0402 0 (649.2) 0.984 3.609 (0.361) 0.0004 0.0001
0201-0201/0102-0604 0.642 (0.584) 0.449 3.638 (0.346) 0.0002 0.0001
0201-0201/0401-0402 0.624 (0.512) 0.356 3.694 (0.349) 0.0002 0.0001
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with the high-risk DQA1*0501-DQB1*0201 (23 of 88, 26%),
relatives with DQA1*0201-DQB1*0201/DQA1*0301-
DQB1*0302 (34 of 82, 42%), relatives with DQA1*0201-
DQB1*0201/DQA1*0101-DQB1*0501 (four of 18, 22%), and
relatives with DQA1*0201-DQB1*0201/DQA1*0201-DQB1*0201
(noneof five) (P0.05). Similarly, survival analysisofprogression
to diabetes indicated that DQA1*0201-DQB1*0201/DQA1*0501-
DQB1*0201 was significantly more protective, with 7% diabetes
risk (n  88), than DQA1*0201-DQB1*0201/DQA1*0301-
DQB1*0302, with 28% diabetes risk (n  83, P  0.007), or than
DQA1*0101-DQB1*0501/DQA1*0501-DQB1*0201, with 22%
diabetes risk (n  85, P  0.02). Relatives with DQA1*0201-
DQB1*0201/DQA1*0501-DQB1*0201 had lower 5-yr diabe-
tes risk (7%) than those with DQA1*0201-DQB1*0201/
DQA1*0101-DQB1*0501 (18%, n 18), but the differencewas
not significant (P  0.23). As shown in Table 2, multivariate
analysis indicated that the effect of DQA1*0201-DQB1*0201/
DQA1*0501-DQB1*0201 on T1DM risk is independent from
multiple autoantibody positivity (HR  0.326, se  0.458, P 
0.016), i.e. relatives who carried this genotype were protected
from diabetes, evenwhen positive for multiple autoantibodies.
Among relatives carrying DQA1*0301-DQB1*0301 (in LD
with DR4, and with aspartic acid at position 57 of the DQB
chain) combined with DQA1*0501-DQB1*0201, only 27% ex-
pressedmultiple biochemical autoantibodies. In comparison,
relatives carrying the same DQA1*0301-DQB1*0301 haplotype in
adifferent genotypic combination (for instance,withDQA1*0101-
DQB1*0501,DQA1*0301-DQB1*0302orDQA1*0301-DQB1*0301),
expressed multiple biochemical autoantibodies in 59, 53, and
69%of the cases, respectively. Similarly, life table-estimated risk
of diabetes was significantly different among relatives with
DQA1*0301-DQB1*0301 in those four genotypic combinations
[e.g.DQA1*0301-DQB1*0301/DQA1*0501-DQB1*0201 (n 84,
5-yr diabetes risk 14%), DQA1*0301-DQB1*0301/DQA1*0101-
DQB1*0501 (n 39, 36%), DQA1*0301-DQB1*0302/DQA1*0301-
DQB1*0301 (n  57, 27%), and DQA1*0301-DQB1*0301/
DQA1*0301-DQB1*0301 (n 13, 31%) (P 0.015)]. As shown in
Table 2, multivariate analysis of DQA1*0501-DQB1*0201/
DQA1*0301-DQB1*0301 andpositivity for four autoantibodies in-
dicated that the effect of this genotype on progression to T1DM is
independent frommultiple autoantibody positivity (HR 0.375,
se0.366,P0.007), i.e. relativeswhocarried this genotypewere
protected from diabetes even when positive for multiple
autoantibodies.
Discussion
HLA influences progression to T1DM and disease risk can
be assigned to a given haplotype or genotype (11). However,
it is controversial whether HLA influences the development
of positive autoantibodies, the subsequent progression to
T1DM, or both stages (12–15). With the screening by DPT-1
of more than 90,000 relatives of T1DM patients for cytoplas-
mic ICAs (2), we have had the opportunity to analyze HLA
DQA1 and DQB1 haplotypes and genotypes of 2,817 ICA
relatives. This unique data set allowed us to analyze HLA
haplotypes and genotypes (combinations of both HLA hap-
lotypes) and their influence on autoantibody expression and
progression to diabetes.
As expected, high-risk haplotypes, such as DQA1*0301-
DQB1*0302 and DQA1*0501-DQB1*0201, were the most
prevalent among these ICA relatives. However, 8% of the
relatives had the protective DQA1*0102-DQB1*0602 haplo-
type. The presence of this protective haplotype among ICA
relatives, at risk for T1DM, is consistent with prior reports (9,
14–16) and confirms that DQA1*0102-DQB1*0602-associated
protection against autoantibody expression and progression
to diabetes is not absolute.
Prevalence of expression of multiple biochemical autoan-
tibodies was highest among relatives who carried
DQA1*0301-DQB1*0201 (in LD with DR9) (57% prevalence)
or DQA1*0301-DQB1*0302 (in LD with DR4) (49%), whereas
it was 38% for DQA1*0501-DQB1*0201 relatives. However,
the genotypic combinations associatedwith the highest prev-
alence of multiple biochemical autoantibodies were
DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201 (59%) and
DQA1*0301-DQB1*0302/DQA1*0301-DQB1*0302 (57%). The
DQA1*0501-DQB1*0201 (DR3) haplotype, in other DR3/non-
DR4 genotypes, was associated with a significantly lower risk
of having multiple autoantibodies.
The risk of T1DM significantly and progressively in-
creased with an increasing number of autoantibodies ex-
pressed (e.g. no, one, two, three, and four) when the whole
study population was considered (regardless of HLA geno-
type) and also when carriers of a given haplotype or geno-
type were separately analyzed (as shown in Fig. 2B). Overall,
the influence of HLA genotypes on the prevalence of auto-
antibody positivity and on diabetes risk was similar in di-
rection and magnitude, as shown in Fig. 4. Of note, among
multiple autoantibody-positive relatives, progression to
T1DM was not different by HLA genotype. Furthermore,
multivariate analyses indicated that the influence of most
genotypes was not independent from the expression of au-
toantibodies (Table 2). The number of single or multiple
autoantibody-positive relatives may have been larger than
we measured, given the relatively low sensitivity of the
mIAA assay. Taken together, our observations support
the hypothesis that most HLA DQ genotypes influenced the
development of autoantibodies in relatives of patients with
T1DM, but in relatives expressing multiple autoantibodies,
FIG. 4. Correlation between life table-estimated progression to dia-
betes at 5 yr of follow-up (y-axis) and prevalence of subjects expressing
a biochemical autoantibody (of GAD65A, ICA512A, and mIAA)
(x-axis), by genotypes. Only genotypes present in more than 15 sub-
jects were included.
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T1DM risk or protectionwas not further determined byHLA
DQ.
DQA1*0102-DQB1*0602 might be an exception: it de-
creased the risk of single and multiple autoantibody expres-
sion, with 80% of relatives with this haplotype being auto-
antibody negative and only 8% of them being positive for
multiple biochemical autoantibodies. It also decreased the
risk of diabetes, and we found that this effect was indepen-
dent from the number of positive autoantibodies. However,
it should be noted the small numbers of relativeswho carried
this haplotype and expressed autoantibodies, and thus, these
findings warrant additional studies. In addition, the protec-
tive effect was not absolute as some relatives expressed au-
toantibodies and progressed to diabetes.
Less common haplotypes such as DQA1*0201-DQB1*0303
(in LD with DR7) or DQA1*0101-DQB1*0503 (DR14) have
been previously reported as protective against -cell auto-
immunity (17, 18). We confirmed the protective effect of both
haplotypes for autoantibody expression. However, we could
not find a significant difference in diabetes risk among rel-
atives with DQA1*0101-DQB1*0503. This may be due to
small numbers of those individuals or to a weaker protective
effect of DQA1*0101-DQB1*0503, compared with DQA1*0102-
DQB1*0602. Alternatively, it may be due to a nondominant effect
of this protective haplotype when paired with a high-risk haplo-
type because in our study population of ICA relatives, most
subjects with a protective haplotype still had DQA1*0501-
DQB1*0201orDQA1*0301-DQB1*0302on theother chromosome.
None of the genotypes containing DQA1*0201-DQB1*0303 or
DQA1*0101-DQB1*0503 seemed to influenceT1DMrisk indepen-
dently from autoantibody expression. As stated above, this is in
contrast to patients carrying DQA1*0102-DQB1*0602, who even
when autoantibody positive, may be protected from progression
to T1DM within the time frame of this study.
The possible protection afforded by DQA1*0102-DQB1*0602
seems to be dominant in that even when paired with high-risk
haplotypes (DQA1*0301-DQB1*0302 orDQA1*0501-DQB1*0201),
this haplotype still decreased the expression of biochemical auto-
antibodies and the risk of progression to diabetes. Thus, the 5-yr
diabetes risk inDQA1*0102-DQB1*0602/DQA1*0301-DQB1*0302
and DQA1*0102-DQB1*0602/DQA1*0501-DQB1*0201 relatives
was, respectively, 2 and 3%.Due to the previously described high
prevalence of abnormal glucose tolerance in this population, (3), it
is possible that progression to disease in those antibody-positive
relatives will occur later.
The data indicate that some alleles, even those with the
reported protective aspartic acid at position 57 (19, 20), can
be associated with high risk of autoantibody expression and
progression to diabetes in a genotypic-specific manner, i.e.
depending on the identity of the second haplotype. An ex-
ample of how a genotype may confer a risk that is different
from that predicted by the two haplotypes expressed is
DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302, the high-
est risk heterozygous genotype. Given the large data set, we
could analyze a number of less common genotypes with the
indication that specific combinations of haplotypeswere par-
ticularly pathogenic or protective. For example, DQA1*0201-
DQB1*0201 (DR7) combined with DQA1*0501-DQB1*0201
was associated with lower prevalence of expression of mul-
tiple biochemical autoantibodies (25%) and diabetes risk (7%
at 5 yr) than when the same haplotype DQA1*0201-
DQB1*0201 is combined with DQA1*0301-DQB1*0302 (41%
multiple autoantibody positivity, 28% diabetes risk) or even
with the neutral DQA1*0101-DQB1*0501 (22% multiple auto-
antibody positivity, 18% diabetes risk). Similarly, DQA1*0301-
DQB1*0301 combined with DQA1*0501-DQB1*0201 was less
diabetogenic (5-yr risk:14%) than DQA1*0301-DQB1*0301/
DQA1*0301-DQB1*0302 (27%), DQA1*0301-DQB1*0301/
DQA1*0101-DQB1*0501 (36%), or DQ0301-DQB1*0301/
DQA1*0301-DQB1*0301 (31%). Of note, as illustrated in Table
2, DQA1*0501-DQB1*0201 combined with DQA1*0301-
DQB1*0301, DQA1*0501-DQB1*0301, or DQA1*0201-DQB1*0201
had a low diabetogenic effect, independent from antibody
expression.
In conclusion, the findings in the current study indicate that
HLADQ haplotypes and genotypes predict biochemical autoan-
tibodyexpression. In relativesexpressingmultipleautoantibodies,
diabetes risk or protection was not further determined by HLA
DQ, with the possible exception of DQA1*0102-DQB1*0602. Spe-
cific combinations of haplotypes (genotypes) were particularly
protective (e.g. DQA1*0201-DQB1*0201/DQA1*0501-DQB1*0201
and DQA1*0301-DQB1*0301/DQA1*0501-DQB1*0201) for auto-
antibody expression and progression to T1DM.
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